Iboxamycin

An antibiotic used to treat bacterial infections

Iboxamycin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Iboxamycin is a novel antibiotic belonging to the aminoglycoside class, designed to combat bacterial infections caused by multidrug-resistant strains. It is particularly effective against Gram-positive bacteria and certain Gram-negative bacteria.

Mechanism of Action

Iboxamycin functions by binding to the bacterial ribosome, specifically targeting the 16S rRNA within the 30S subunit. This binding interferes with the protein synthesis process, ultimately leading to bacterial cell death. The unique structure of iboxamycin allows it to evade common resistance mechanisms that affect other aminoglycosides, such as aminoglycoside-modifying enzymes and efflux pumps.

Development and Synthesis

The development of iboxamycin was driven by the need for new antibiotics capable of overcoming resistance. Its synthesis involves the modification of the aminoglycoside core to enhance its binding affinity and reduce susceptibility to resistance mechanisms. The chemical structure of iboxamycin is characterized by the presence of an iboxazole ring, which is crucial for its activity against resistant bacterial strains.

Clinical Use

Iboxamycin is primarily used in the treatment of severe infections caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). It is administered intravenously and is often reserved for cases where other antibiotics have failed.

Side Effects

As with other aminoglycosides, iboxamycin can cause nephrotoxicity and ototoxicity, particularly with prolonged use or in patients with pre-existing kidney conditions. Monitoring of kidney function and hearing is recommended during treatment.

Resistance

While iboxamycin is designed to overcome many common resistance mechanisms, the potential for resistance development still exists. Bacteria may develop mutations in the ribosomal binding site or acquire resistance genes that confer protection against iboxamycin.

Research and Future Directions

Ongoing research is focused on further understanding the resistance mechanisms that could affect iboxamycin and developing derivatives with enhanced efficacy and safety profiles. Studies are also exploring its use in combination therapies to broaden its spectrum of activity and reduce the likelihood of resistance development.

Related Pages

• Antibiotic resistance
• Aminoglycoside
• Bacterial infections
• Gram-positive bacteria
• Gram-negative bacteria